Your Health, We Care
Release date: 2026-03-24 17:00:21 Article From: Lucius Laos Recommended: 2
Enasidenib helps restore the normal differentiation of leukemia cells by inhibiting the activity of mutant IDH2 enzymes. During treatment, it may also affect the function of normal cells, leading to a range of adverse reactions.
Seek immediate medical attention if any of the following side effects occur while taking Enasidenib:
Nervous system: Restlessness, confusion, dizziness, syncope, lightheadedness, loss of consciousness, seizures, severe drowsiness, abnormal lethargy/sluggishness/tiredness/weakness/fatigue.
Cardiovascular system: Cyanosis of the lips/nails/skin, chest pain, rapid heartbeat.
Respiratory system: Cough, cough with pink frothy sputum, dyspnea, shortness of breath/difficulty breathing/with rales, irregular/faster/slower/superficial breathing, tachypnea/superficial breathing.
Digestive system: Nausea.
Musculoskeletal system: Bone pain, muscle or joint pain, muscle spasms.
Skin, mucous membranes/edema: Pale skin, yellowing of the skin or eyes, swelling of the neck/inguinal/axillary regions, swelling of the arms/feet/calves, swelling of the face/ankles/hands.
Psychological system: Depression, hostility, irritability.
Systemic and infection-related symptoms: Chills, fever, general malaise, increased sweating, sore throat.
Urinary system: Decreased urine output.
Consult a healthcare professional if any of the following side effects persist, cause distress, or if you have any related questions:
Altered taste, decreased appetite, diarrhea, loss of taste, vomiting.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：1832025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：4202024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：1892025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：2052025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：1822025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：2152025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：2022025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：1852025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
